Mirzotamab is an IgG1?? monoclonal antibody specifically designed to target CD276 (also known as B7-H3), a protein frequently overexpressed in various tumor cells. This antibody exhibits potent anti-tumor properties. In its conjugated form, mirzotamab is linked to Clezutoclax, a BCL-2 family inhibitor, creating the antibody-drug conjugate (ADC) known as Mirzotamab Clezutoclax (ABBV-155). This ADC is currently under investigation for its efficacy in combination with taxane therapy in the treatment of relapsed or refractory solid tumors, highlighting its potential as a therapeutic in oncological research.
Mirzotamab is an IgG1?? monoclonal antibody specifically designed to target CD276 (also known as B7-H3), a protein frequently overexpressed in various tumor cells. This antibody exhibits potent anti-tumor properties. In its conjugated form, mirzotamab is linked to Clezutoclax, a BCL-2 family inhibitor, creating the antibody-drug conjugate (ADC) known as Mirzotamab Clezutoclax (ABBV-155). This ADC is currently under investigation for its efficacy in combination with taxane therapy in the treatment of relapsed or refractory solid tumors, highlighting its potential as a therapeutic in oncological research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
